Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allied Minds Names Joseph Pignato as CFO

1 Sep 2015 07:03

RNS Number : 5800X
Allied Minds PLC
01 September 2015
 



Allied Minds Names Joseph Pignato as Chief Financial Officer

 

· Joe has served as a senior advisor to fast-growing businesses for almost two decades, and brings a wide range of experience working with venture capital firms as well as start-up and publicly traded companies.

 

· Joe was most recently CFO of Swipely, where he helped oversee growth in sales under management to more than $4 billion. He also served in senior management positions at Charles River Ventures, Prism Ventures and Lightbridge.

 

 

Boston (September 01, 2015) - Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, today announced that Joseph Pignato is joining its executive management team as Chief Financial Officer.

 

Joe's experience as a senior advisor to fast-growing businesses spans almost two decades. After gaining experience in accounting at PKF Worldwide and Deloitte, Joe developed expertise in the effective deployment of venture capital for early stage companies during his tenure as CFO of Charles River Ventures; as General Partner, Chief Operating Officer and CFO of Prism Ventures; and as a Board Member of the Slater Technology Fund. Joe also applied his own skills in value creation while serving as Director of Finance at Lightbridge, a NASDAQ-listed firm that he helped to take public; and as CFO at Swipely, which grew to more than $4 billion in sales under management during his tenure.

 

"It's a privilege to join Allied Minds, a company that brings together a unique mix of entrepreneurial talent and seasoned, global expertise," said Joe. "Allied Minds' dynamic and fast-moving environment is exciting, and I look forward to working with the team to help develop and support new companies in their innovative, and potentially market-disruptive, work."

 

Joe's broad strengths in finance, investor relations and operations, as well as his skills as a mentor to management teams, will be an asset to Allied Minds and its 22 subsidiary companies. At Allied Minds, Joe is joining an expanding team of experienced senior managers who are engaged in advising the portfolio companies on how to navigate high-growth strategies as they commercialize sophisticated technologies developed at U.S. federal and academic research centers.

 

"Joe brings a robust track record of managing and fostering early stage companies into financial stability and growth," said Chris Silva, Chief Executive Officer of Allied Minds. "I am confident that he will further enhance our ability to transform U.S. inventions into commercial innovation. We are delighted to have him on board the Allied Minds team."

 

More information about Allied Minds can be found at www.alliedminds.com

 

Media Contact:

 

US

Christine Dunn

ArcPoint Strategic Communications

cdunn@arcpointstrategy.com

617.484.1660 x101

 

UK

Ben Atwell / Matthew Cole

FTI Consulting

+44 (0) 20 3727 1000

 

About Allied Minds, Inc.

Allied Minds is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

 

 

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risk and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Prospectus Rules, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

###

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPKDDDOBKDOFN
Date   Source Headline
16th Jul 20217:00 amRNSTransaction in Own Shares
13th Jul 20217:00 amRNSTransaction in Own Shares
7th Jul 20217:00 amRNSTransaction in Own Shares
5th Jul 20217:00 amRNSTransaction in Own Shares
2nd Jul 20217:00 amRNSTransaction in Own Shares
1st Jul 20217:00 amRNSTransaction in Own Shares
30th Jun 20217:00 amRNSTransaction in Own Shares
29th Jun 20217:00 amRNSTransaction in Own Shares
28th Jun 20217:00 amRNSTransaction in own shares
25th Jun 20217:00 amRNSTransaction in own shares
24th Jun 20217:00 amRNSTransaction in own shares
23rd Jun 20217:00 amRNSPortfolio company update and share buyback
16th Jun 20214:41 pmRNSSecond Price Monitoring Extn
16th Jun 20214:36 pmRNSPrice Monitoring Extension
3rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
3rd Jun 20214:35 pmRNSPrice Monitoring Extension
1st Jun 20217:00 amRNSOcuTerra Therapeutics Series B Second Close
24th May 20214:41 pmRNSSecond Price Monitoring Extn
24th May 20214:36 pmRNSPrice Monitoring Extension
18th May 20214:40 pmRNSSecond Price Monitoring Extn
18th May 20214:35 pmRNSPrice Monitoring Extension
12th May 20215:28 pmRNSResult of AGM
11th May 20217:00 amRNSBlock listing Interim Review
11th May 20217:00 amRNSBlock listing Interim Review
11th May 20217:00 amRNSBlock listing Interim Review
28th Apr 20217:00 amRNSOcuTerra Therapeutics Raises Series B Financing
15th Apr 20217:00 amRNSBlock Listing Application
13th Apr 20217:00 amRNSOrbital Sidekick Closes $16m Series A Financing
9th Apr 20217:00 amRNSCapital Markets Day
6th Apr 20217:00 amRNSNotice of AGM
1st Apr 20215:34 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSAnnual results release
29th Mar 20214:28 pmRNSHolding(s) in Company
22nd Mar 20217:00 amRNSNotice of results - update
18th Mar 20214:41 pmRNSSecond Price Monitoring Extn
18th Mar 20214:36 pmRNSPrice Monitoring Extension
11th Mar 20214:36 pmRNSPrice Monitoring Extension
1st Mar 20219:00 amRNSNotice of Results
23rd Feb 20217:00 amRNSBridgeComm Advances Development of MOCA Technology
2nd Feb 20219:33 amRNSDirector/PDMR Shareholding
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSDirectorate Change
8th Jan 20214:36 pmRNSPrice Monitoring Extension
4th Jan 20215:15 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSStrategic update
24th Dec 20207:00 amRNSOrbital Sidekick Series A Financing
21st Dec 20203:25 pmRNSFederated Wireless partners with TESSCO
1st Dec 20203:35 pmRNSTotal Voting Rights
23rd Nov 20204:36 pmRNSPrice Monitoring Extension
19th Nov 20207:00 amRNSShareholder engagement update on 2020 AGM vote

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.